Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, Dalekos GN, Goulis J, Berg T, Buti M, Kim SU, Kim YJ. Chun HS, et al. Among authors: dalekos gn. J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011. Epub 2023 Sep 19. J Hepatol. 2024. PMID: 37734683
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 Study Group. Zachou K, et al. Among authors: dalekos gn. Liver Int. 2010 Mar;30(3):430-7. doi: 10.1111/j.1478-3231.2009.02140.x. Epub 2009 Oct 16. Liver Int. 2010. PMID: 19840253
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Mederacke I, et al. Among authors: dalekos gn. Antivir Ther. 2012;17(2):305-12. doi: 10.3851/IMP1926. Epub 2011 Oct 24. Antivir Ther. 2012. PMID: 22293066
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis.
Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Kabaçam G, et al. Among authors: dalekos gn. Turk J Gastroenterol. 2012;23(5):560-8. doi: 10.4318/tjg.2012.0538. Turk J Gastroenterol. 2012. PMID: 23161302 Free article. Clinical Trial.
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Heidrich B, et al. Among authors: dalekos gn. Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102. Hepatology. 2014. PMID: 24585488
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. Papatheodoridis GV, et al. Among authors: dalekos gn. J Viral Hepat. 2015 Feb;22(2):120-7. doi: 10.1111/jvh.12283. Epub 2014 Jul 15. J Viral Hepat. 2015. PMID: 25040685
310 results